Lyon, October 27th, 2016 – Theranexus, a clinical-stage biopharmaceutical company, announced today that the first patient has been recruited in the study entitled “safety and efficacy of THN102 on sleepiness in narcolepsy patients” (NCT02821715), a phase II clinical study evaluating the efficacy and tolerance of THN102 in the treatment of excessive daytime sleepiness associated with narcolepsy in adult patients.
Lyon, October 4th 2016 – Theranexus, a clinical-stage biopharmaceutical company, announced today that it’s most advanced drug candidate, THN102, has received an Orphan Drug Designation (ODD) from the American regulatory agency, the FDA, for the treatment of narcolepsy, a rare and highly debilitating sleep/wake disorder.
Lyon, 20th of September 2016 – Theranexus, a clinical-stage biopharmaceutical company, has announced today that it has received funding from the FUI (French Inter-ministry Fund) for its project CX-COG (FUI AAP22) which has been approved by the competitiveness clusters Lyonbiopôle and Atlanpôle Biothérapies. This project, which will be carried out in collaboration with the team of Prof. Régis Bordet (Lille University, Lille University Hospital, Inserm) and the company Synerlab, concerns the pharmaceutical formulation development and clinical validation of the efficacy of product THN201 in the treatment of neurocognitive impairment particularly associated with Alzheimer’s disease.
Lyon, May 17th 2016 –Theranexus, a clinical-stage biopharmaceutical company, announced today top-line results from its proof of concept clinical trial in Excessive Daytime Sleepiness (EDS) induced by sleep deprivation in healthy volunteers. Those results show a beneficial effect of THN102 (combination of modafinil and flecainide, repurposed at low dose as glial connexin modulator) on outcomes measuring vigilance and cognition throughout the sleep deprivation and when compared to the standard of care modafinil.
Paris, March 30th 2016 –Theranexus, a biopharmaceutical company already in the clinical trial stages of its lead project, has announced the publication of an article in Sleep, a peer-reviewed journal and a recognised international reference point for research into sleep disorders.
Paris, 19th October 2015 – Biotechnology company Theranexus—founded by Franck Mouthon, CEO, and Mathieu Charvériat, Scientific Director—is pleased to announce the launch of the clinical efficacy phase of its lead program, THN102, in the treatment of sleep disorders.
Based on the positive results obtained in phase I, which focused on the safety of THN102, Theranexus was granted authorisation to assess the efficacy of the product. Coordinated by IRBA’s Fatigue and Vigilance unit headed by Mounir Chennaoui and backed by the French Army’s Central Pharmacy for the manufacture and release of experimental medication, the Phase-Ib study is being conducted at the Percy Military Hospital (HIA) in Clamart near Paris. Head doctor, Fabien Sauvet, a sleep specialist from the IRBA, is managing the double-blind trial with placebo, active comparator and the product THN102 being administered in three doses to sleep-deprived volunteers. The trial is designed to assess the capacity of THN102, in particular, to keep subjects awake and maintaining their level of cognitive performance (attention, memory). The study has the financial backing of the French Defence Procurement and Technology Agency (DGA) in the framework of the government’s “RAPID” program that supports defence-sector R&D projects.
Paris, July 15, 2015 – Created by Franck Mouthon, CEO, and Mathieu Charvériat, CSO, the biotechnology company Theranexus has announced positive results in phase 1 of its first program in the treatment of narcolepsy referred to as THN102, as well as the launch of efficacy studies.
Theranexus, a CEA spin-off, designs and develops drug combinations to improve the efficacy and safety of certain neurological and psychiatric treatments.
Bolstered by the €3.6 million raised for the THN102 program, Theranexus aims to treat narcolepsy, a disabling orphan disease chronically affecting sleep-wake cycles.
This program is based on the combination of a reference psychostimulant and a small molecule repositioned at a low dose as modulator of specific connexins in the central nervous system.
Theranexus, société essaimée du CEA annonce la réalisation d’une levée de fonds pour un montant global de 3,6 M€ auprès d’Auriga Partners, de CEA Investissement (via son fonds Amorçage Technologique Investissement), d’Emergence Innovation 1, géré par Sofimac Partners, et de Rhône-Alpes Création.